Press Release: Available for Immediate Release
The MDS Hub, run by Scientific Education Support (SES) in partnership with the European LeukemiaNet (ELN), has continued to promote significant developments in the treatment and research of myelodysplastic syndromes (MDS) throughout Quarter 2 of 2021.
The MDS Hub has provided news on the latest advancements in clinical sciences relating to MDS, including updates on ongoing clinical trials and information about leading-edge discoveries in medicines and therapeutic regimens.
Speaking about the success of the MDS Hub’s activity, Mia Hill, IME director at Scientific Education Support, said:
“During this quarter, we had a chance to cover multiple virtual congresses and update our audience with advancements in the field. In April, we provided media coverage for the Acute Leukemia Forum 2021, where we reported about scientific and educational sessions on hematologic malignancies aimed to educate healthcare professionals treating patients with MDS/acute myeloid leukemia (AML). We focused mainly on advances in myelodysplasia, therapies in AML for induction, post-remission and relapse, and bone marrow transplantation.”
In June this year, the MDS Hub was also given the opportunity to provide an array of information about current trends in hematologic malignancies at the 2021 ASCO Annual Meeting. Most sessions were focused on the latest combination therapies, validation, and efficacy of new regimens, followed by genetic signature identification and CAR T-cell therapies.
Discussing the hub’s reporting on the 26th Congress of the European Hematology Association (EHA2021), Mia Hill said:
“We shared more updates on translational and clinical research in MDS by virtually attending and reporting on the 26th Congress of the European Hematology Association (EHA2021). The most popular topics included the impact of changes in cytogenetics on neoplastic activity, use of hypomethylating agents, combination therapies, and dose-related toxicities during treatment for patients with MDS. Highlights of EHA2021 were also provided by Theo de Witte, Radboudumc, Nijmegen, NL. In his interview with the MDS Hub, de Witte provided an overview of studies investigating novel agents, such as sabatolimab and magrolimab, and new ways to look at myelodysplastic immune compositions, such as identification of immune cell subsets.
Furthermore, a meeting with the esteemed members of our steering committee was held in May. Our members help us to identify the most interesting and impactful clinical research in hematologic oncology.
We would like to take this opportunity to show our gratitude for our existing supporters— Novartis, Bristol Myers Squibb, Geron Corporation, and Takeda”
For more information on the MDS Hub, please visit mds-hub.com.
For media enquiries, or to explore collaboration opportunities, please contact firstname.lastname@example.org
About myelodysplastic syndromes (MDS)
Myelodysplastic syndromes (MDS)—also known as myelodysplasia—are a type of rare blood cancer where there are not enough healthy blood cells. There are many different types of MDS. Some types can stay mild for years, whereas others are more serious. MDS can affect people of any age but are most common in adults over the age of 70 years.
About the MDS Hub
The MDS Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education about MDS. Our aim is to enhance knowledge of MDS through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
The MDS Hub is the solution for a time-stretched HCP to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders and endorsed by expert societies the MDS Hub supports HCPs worldwide.
The MDS Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
MDS Hub supporters
Funding for our hubs are made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert Steering Committee.All content is independent, and the educational supporters are allowed no influence on the content.
- Bristol Myers Squibb
If you are interested in becoming an MDS supporter, please contact email@example.com
About Scientific Education Support (SES)
SES is a medical education company with projects such as community physician education though our therapy hubs, community awareness and education through our ‘KNOW’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.
Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology, which includes the Lymphoma Hub, AML Hub, Multiple Myeloma Hub, GvHD Hub, MPN Hub, and ALL Hub.
About the European LeukemiaNet
The European LeukemiaNet cooperates with 220 participating centers in 44 countries, with more than 1,000 researchers and clinicians. The objective is to integrate about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry, and SMEs across Europe to form a network promoting cooperative research for curing leukemia.